Advances in Lymphoma

Chronic Lymphocytic Leukemia/Small Lymphocytic

Lymphoma

Ibrutinib Monotherapy

GS-9973 and Idelasib in Patients With R/R CLL

ABT-199 in Patients With R/R CLL/SLL

Hodgkin Lymphoma

ABVD With and Without Bleomycin and/or Dacarbazine

Brentuximab Vedotin Followed by ABVD in Patients With Untreated

NHL

Single-Agent Brentuximab Vedotin in R/R Hodgkin Lymphoma

Follicular Lymphoma

Prognostic Value of PET-CT After FL Therapy in FL

FOLL05, 5-Year Follow-up

Alliance/CALGB 50803Lenalidomide Plus Rituximab for Untreated

FL

ROMULUSPolatuzumab Vedotin or Pinatuzumab Vedotin

Plus Rituximab in Patients With R/R FL

Diffuse Large B-Cell Lymphoma

Two Different R-CHOP Variants

ABT-199 for DLBCL

Monitoring MRD Using Cellular and Acellular Blood DNA

Mantle Cell Lymphoma

R-CHOP vs VR-CAP for BMT-Ineligible Newly Diagnosed

Patients With MCL

Subcutaneous Bortezomib in Relapsed MCL

Safety of Ibrutinib in R/R MCL

T-Cell Lymphoma

Alisertib for PTCL

Response to Romidepsin by Number of Lines of Prior Therapies

in R/R PTCL

Topical SHP-141 for CTCL

Outcomes of Patients With PTCL From the BCCA Registry After

Standard Chemotherapy

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)